Breaking News Instant updates and real-time market news.

VBLT

VBL Therapeutics

$4.55

0.05 (1.11%)

08:21
06/19/17
06/19
08:21
06/19/17
08:21

VBL Therapeutics provides update on long-term survival in Phase 2 trials

VBL Therapeutics provided an update on the long term status and survival of patients from three completed Phase 2 trials, which investigated the company's lead candidate, VB-111, respectively in recurrent glioblastoma, or rGBM, recurrent platinum-resistant ovarian cancer and radioiodine refractory differentiated thyroid cancer. All three trials had previously shown signals of an overall survival benefit for VB-111. The company has continued to follow the survival of patients from these trials. "We are pleased to report that in all three indications over 50% of patients have achieved long term survival following treatment with VB-111 as detailed below. Each of these Phase 2 trials enrolled difficult to treat patients for whom prior treatments had failed," said Prof. Dror Harats, CEO of VBL Therapeutics. "In addition, we continue to follow patients from our Phase 1 studies, who responded to VB-111 and have now survived for more than 5 years, although they were end-stage patients whose tumors had previously progressed in spite of several lines of therapy. We are now conducting pivotal trials with the goal of investigating these survival benefits and providing data to support regulatory approval and commercialization of VB-111. Our GLOBE pivotal trial in rGBM has completed enrollment and we expect top line data from the full dataset becoming available in early 2018. We expect patient enrollment in our planned Phase 3 OVAL study in ovarian cancer to begin in the second half of 2017. In addition, we plan to launch a combination study of VB-111 with a checkpoint inhibitor in lung cancer by year-end 2017."

VBLT VBL Therapeutics
$4.55

0.05 (1.11%)

11/29/16
ROTH
11/29/16
NO CHANGE
Target $17
ROTH
Buy
VBL Therapeutics thyroid study points in right direction, says Roth Capital
Roth Capital analyst Joseph Pantginis notes that VBL Therapeutics has announced positive follow-up overall survival data from the Phase 2 thyroid cancer study with VB-111. The analyst believes VB-111 represents a "strong potential option" for patients with recurrent glioblastoma and looks forward to clinical progress in the Phase 3 rGBM study. Pantginis projects upside from future clinical updates, expansion opportunities for new indications as well as partnership potential for VB-111. He reiterates a Buy rating and $17 price target on the shares.
11/29/16
ROTH
11/29/16
NO CHANGE
ROTH
VBL Therapeutics mentioned positively at Roth Capital
06/28/16
HCWC
06/28/16
INITIATION
Target $11
HCWC
Buy
VBL Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth started VBL Therapeutics with a Buy rating and $11 price target.

TODAY'S FREE FLY STORIES

FEYE

FireEye

11:45
06/27/17
06/27
11:45
06/27/17
11:45
Options
FireEye call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Jul

11:45
06/27/17
06/27
11:45
06/27/17
11:45
General news
Treasury's $40 B 4-week bill sale was poorly subscribed »

Treasury's $40 B…

BT

BT Group

$18.68

0.06 (0.32%)

11:42
06/27/17
06/27
11:42
06/27/17
11:42
Upgrade
BT Group rating change  »

BT Group upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:35
06/27/17
06/27
11:35
06/27/17
11:35
General news
Treasury Option Action: a round of call buying in the belly »

Treasury Option Action: a…

OSUR

OraSure

$15.72

0.17 (1.09%)

11:31
06/27/17
06/27
11:31
06/27/17
11:31
Recommendations
OraSure analyst commentary  »

OraSure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

XLF

Financial Select Sector

$24.19

0.17 (0.71%)

11:30
06/27/17
06/27
11:30
06/27/17
11:30
Options
SPDR Financial calls outpace puts nearly 25:1 »

SPDR Financial calls…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KITE

Kite Pharma

$100.43

-0.23 (-0.23%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Options
Kite Pharma call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

ANY

Sphere 3D

$0.20

0.0275 (16.08%)

11:25
06/27/17
06/27
11:25
06/27/17
11:25
Conference/Events
Sphere 3D to host special shareholder meeting »

Special shareholder…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jun

MRK

Merck

$66.14

0.215 (0.33%)

11:20
06/27/17
06/27
11:20
06/27/17
11:20
Periodicals
Merck confirms computer network 'compromised' by global hack »

Merck stated in a series…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

11:20
06/27/17
06/27
11:20
06/27/17
11:20
General news
Fed's Harker still backs another rate hike this year »

Fed's Harker still…

BLK

BlackRock

$425.20

0.51 (0.12%)

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Hot Stocks
BlackRock to acquire Cachematrix »

BlackRock has entered…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

11:17
06/27/17
06/27
11:17
06/27/17
11:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

11:16
06/27/17
06/27
11:16
06/27/17
11:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:15
06/27/17
06/27
11:15
06/27/17
11:15
General news
Breaking General news story  »

4-Week Bill Auction to be…

PSX

Phillips 66

$80.96

0.72 (0.90%)

, CVX

Chevron

$104.76

0.62 (0.60%)

11:11
06/27/17
06/27
11:11
06/27/17
11:11
Hot Stocks
Chevron Phillips Chemical names Mark Lashier CEO »

Chevron Phillips Chemical…

PSX

Phillips 66

$80.96

0.72 (0.90%)

CVX

Chevron

$104.76

0.62 (0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

11:10
06/27/17
06/27
11:10
06/27/17
11:10
General news
Today's U.S. reports »

Today's U.S. reports…

ALDR

Alder Biopharmaceuticals

$18.70

-1 (-5.08%)

11:03
06/27/17
06/27
11:03
06/27/17
11:03
Recommendations
Alder Biopharmaceuticals analyst commentary  »

Piper reiterates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Jul

AA

Alcoa

$32.33

1.15 (3.69%)

11:00
06/27/17
06/27
11:00
06/27/17
11:00
Options
Alcoa attracts call buying »

Alcoa attracts call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
FX Action: USD-CAD »

FX Action: USD-CAD fell…

11:00
06/27/17
06/27
11:00
06/27/17
11:00
General news
Breaking General news story  »

Philadelphia Federal…

HCC

Warrior Met Coal

$15.88

-0.31 (-1.91%)

10:58
06/27/17
06/27
10:58
06/27/17
10:58
Downgrade
Warrior Met Coal rating change  »

Follow-up: Warrior Met…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BV

Bazaarvoice

$4.80

-0.1 (-2.04%)

10:56
06/27/17
06/27
10:56
06/27/17
10:56
Conference/Events
Bazaarvoice management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 28

    Jun

  • 29

    Jun

  • 11

    Jul

CBI

CB&I

$16.50

2.1 (14.58%)

, TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Periodicals
Court rules for Chicago Bridge in Westinghouse case, Reuters says »

The Delaware Supreme…

CBI

CB&I

$16.50

2.1 (14.58%)

TOSBF

Toshiba, also use TOSYY

$2.69

0.03 (1.13%)

TOSYY

Toshiba, also use TOSBF

$15.91

-0.065 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:55
06/27/17
06/27
10:55
06/27/17
10:55
Conference/Events
Federal Reserve Bank of Philadelphia President speaks on economic outlook »

Philadelphia Federal…

LTRX

Lantronix

$2.37

-0.08 (-3.27%)

10:54
06/27/17
06/27
10:54
06/27/17
10:54
Conference/Events
Lantronix management to meet with Needham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.